In order to evaluate LIF effect on the Hippo pathway in GC, which has neither been studied nor described, Hippo pathway status and especially Hippo tumour suppressor kinase LATS1/2 activation was analysed upon LIF treatment. The gene discussed is LATS1; the disease is gastric cancer.